Five years ago, a group of high-risk skin cancer patients received a bespoke vaccine. The data is finally in, and the results ...

By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...

The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

Jan 22 (Reuters) - Moderna does not plan to invest in new late-stage vaccine trials because of growing opposition to ...

If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock ...

CEO Stéphane Bancel said on Thursday that his company will not fund further late-stage development of vaccines as the U.S.

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene (mRNA-4157), show an impressive 49% reduction in the risk of disease ...

In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

Moderna Inc.’s chief executive officer said the company doesn’t plan to invest in new late-stage vaccine trials because of ...

Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or ...